Details of the Drug Pharmacogenomic Perturbation Atlas

Celastrol Drug Info

Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid

Cross-matching ID

PubChem CID

122724

ChEBI ID

CHEMBL301982

CAS Number

CAS 34157-83-0

TTD Drug ID

D0I9XH

General Information of Drug (ID: DMWQIJX)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Protein processing in endoplasmic reticulum	2.07	8.76e-3	127/171 (74.27%)	HSPA1A;HSPA6;DNAJB1;...
Legionellosis	1.99	1.31e-2	51/57 (89.47%)	HSPA1A;HSPA6;HSPA8;...
Spliceosome	1.98	8.76e-3	101/150 (67.33%)	HSPA1A;HSPA6;HSPA8;...
Fluid shear stress and atherosclerosis	1.86	2.41e-2	123/139 (88.49%)	HMOX1;DUSP1;FOS;...
Estrogen signaling pathway	1.77	4.55e-2	119/137 (86.86%)	HSPA1A;HSPA6;HSPA8;...
Lysine degradation	-1.69	4.45e-2	51/63 (80.95%)	ACAT2;SETD2;EZH1;...
Bacterial invasion of epithelial cells	-1.70	4.53e-2	59/77 (76.62%)	HCLS1;CRK;CTNNA1;...
Diabetic cardiomyopathy	-1.70	4.53e-2	162/203 (79.8%)	ATP5F1D;NDUFB7;ATP5F1B;...
Fatty acid biosynthesis	-1.75	3.85e-2	16/18 (88.89%)	ACSL6;ACSBG1;FASN;...
Citrate cycle (TCA cycle)	-1.82	1.89e-2	30/30 (100%)	SDHB;IDH3A;MDH1;...
Oxidative phosphorylation	-1.84	1.84e-2	93/133 (69.92%)	ATP5F1D;NDUFB7;ATP5F1B;...
Fatty acid degradation	-1.85	1.78e-2	40/43 (93.02%)	ECI1;ADH1C;ACSL5;...
Fatty acid elongation	-1.90	1.51e-2	19/27 (70.37%)	MECR;HADHB;HACD1;...
Biosynthesis of unsaturated fatty acids	-1.92	1.36e-2	21/27 (77.78%)	FADS2;HACD1;ELOVL2;...
Nitrogen metabolism	-1.93	1.13e-2	16/17 (94.12%)	CA9;CA3;CA2;...
Steroid biosynthesis	-1.96	1.13e-2	19/20 (95%)	CYP51A1;LSS;TM7SF2;...
Propanoate metabolism	-1.99	1.13e-2	30/34 (88.24%)	BCKDHA;ACAT2;BCKDHB;...
Valine, leucine and isoleucine degradation	-2.19	0.00e+0	42/48 (87.5%)	BCKDHA;ACADSB;MCCC1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast carcinoma

Normal (Epithelial)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HME1	CVCL_2950	Homo sapiens	0.04uM - 10uM	3H, 24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.04uM - 10uM	3H, 6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Transformed)

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.04uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HFL1	CVCL_4295	Homo sapiens	10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H